Plus Therapeutics Inc
PSTV
查看详细走势图
0.215USD
-0.028-11.49%
收盘 03/30, 16:00（美东）报价延迟15分钟
111.66总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-11.49%
5天
-13.27%
1月
-28.97%
6月
-74.13%
今年开始到现在
-58.03%
1年
-81.47%
查看详细走势图
TradingKey Plus Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Plus Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名117/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.70。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Plus Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Plus Therapeutics Inc亮点
亮点风险
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
业绩增长期
公司处于发展阶段，最新年度总收入5.21M美元
利润高增长
公司净利润处于行业前列，最新年度总收入5.21M美元
估值低估
公司最新PE估值-0.80，处于3年历史低位
机构加仓
最新机构持股5.42M股，环比增加20.50%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值2.28M
活跃度降低
近期活跃度降低，过去20天平均换手率0.28
分析师目标
根据
5
位分析师
买入
评级
5.700
目标均价
+2246.64%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Plus Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Plus Therapeutics Inc简介
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
公司代码PSTV
公司Plus Therapeutics Inc
CEOHedrick (Marc H)
网址http://www.plustherapeutics.com/
相关品种
